公开(公告)号：US20220073636A1

公开(公告)日：2022-03-10

申请号：US17522008

申请日：2021-11-09

申请人： Bristol-Myers Squibb Company ,  Domantis Limited

发明人： Steven G. NADLER ,  James K. TAMURA ,  Laura PRICE ,  Robert P. REHFUSS ,  Suzanne J. SUCHARD ,  Anish SURI ,  James William BRYSON ,  Aaron YAMNIUK ,  Steven GRANT ,  Olga IGNATOVICH ,  Philip DREW

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K16/46 ,  C07K16/18

摘要： Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

公开(公告)号：US20160075790A1

公开(公告)日：2016-03-17

申请号：US14950949

申请日：2015-11-24

申请人： Domantis Limited ,  Bristol-Myers Squibb Company

发明人： Steven G. NADLER ,  James K. TAMURA ,  Laura PRICE ,  Robert P. REHFUSS ,  Suzanne J. SUCHARD ,  Anish SURI ,  James William BRYSON ,  Aaron YAMNIUK ,  Steven GRANT ,  Olga IGNATOVICH ,  Philip DREW

IPC分类号： C07K16/28 ,  A61K45/06 ,  C07K16/18 ,  C07K16/46 ,  A61K39/395

CPC分类号： C07K16/2878 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K16/283 ,  C07K16/2833 ,  C07K16/2875 ,  C07K16/2896 ,  C07K16/46 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

摘要： Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

公开(公告)号：US20180051091A1

公开(公告)日：2018-02-22

申请号：US15668305

申请日：2017-08-03

申请人： Bristol-Myers Squibb Company ,  Domantis Limited

发明人： Steven G. NADLER ,  James K. TAMURA ,  Laura PRICE ,  Robert P. REHFUSS ,  Suzanne J. SUCHARD ,  Anish SURI ,  James William BRYSON ,  Aaron YAMNIUK ,  Steven GRANT ,  Olga IGNATOVICH ,  Philip DREW

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K16/46 ,  C07K16/18 ,  A61K39/00 ,  A61K38/00

CPC分类号： C07K16/2878 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K16/283 ,  C07K16/2833 ,  C07K16/2875 ,  C07K16/2896 ,  C07K16/46 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

摘要： Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

公开(公告)号：US20150023976A1

公开(公告)日：2015-01-22

申请号：US14510474

申请日：2014-10-09

申请人： BRISTOL-MYERS SQUIBB COMPANY ,  DOMANTIS LIMITED

发明人： Steven G. NADLER ,  James K. TAMURA ,  Laura PRICE ,  Robert P. REHFUSS ,  Suzanne J. SUCHARD ,  Anish SURI ,  James William BRYSON ,  Aaron YAMNIUK ,  Steven GRANT ,  Olga IGNATOVICH ,  Philip DREW

IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  C07K16/46 ,  C07K16/18

CPC分类号： C07K16/2878 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K16/283 ,  C07K16/2833 ,  C07K16/2875 ,  C07K16/2896 ,  C07K16/46 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

摘要： Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

摘要翻译： 提供了特异性结合人CD40L的抗体多肽。 抗体多肽不激活血小板。 抗体多肽可用于治疗涉及CD40L活化的疾病，例如移植物相关疾病和自身免疫性疾病。 抗体多肽可以是包含单个VH或VK结构域的结构域抗体（dAb）。 抗体多肽的半衰期可以通过将抗体多肽修饰为也可以结合人血清白蛋白（HSA）或另一抗原的双特异性试剂来增加。

公开(公告)号：US20190100595A1

公开(公告)日：2019-04-04

申请号：US16218077

申请日：2018-12-12

申请人： Bristol-Myers Squibb Company ,  Domantis Limited

发明人： Steven G. NADLER ,  James K. TAMURA ,  Laura PRICE ,  Robert P. REHFUSS ,  Suzanne J. SUCHARD ,  Anish SURI ,  James William BRYSON ,  Aaron YAMNIUK ,  Steven GRANT ,  Olga IGNATOVICH ,  Philip DREW

IPC分类号： C07K16/28 ,  A61K45/06 ,  C07K16/18 ,  A61K39/00 ,  A61K38/00

摘要： Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

公开(公告)号：US20170015754A1

公开(公告)日：2017-01-19

申请号：US15259828

申请日：2016-09-08

申请人： Bristol-Myers Squibb Company ,  Domantis Limited

发明人： Anish SURI ,  Steven SHERIFF ,  Suzanne SUCHARD ,  Aaron YAMNIUK ,  Stanley KRYSTEK ,  James TAMURA ,  James BRYSON ,  Steven GRANT ,  Philip DREW

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K16/18

摘要： Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).

摘要翻译： 提供特异性结合人CD40的新表位的抗体多肽。 抗体多肽不表现出CD40激动剂活性。 抗体多肽可用于治疗涉及CD40活化的疾病，例如自身免疫性疾病。 抗体多肽可以是包含单个VL或VH结构域的结构域抗体（dAb）。 抗体多肽的半衰期可以通过将抗体多肽修饰为也可以结合人血清白蛋白（HSA）的双特异性试剂来增加。

公开(公告)号：US20130095109A1

公开(公告)日：2013-04-18

申请号：US13650493

申请日：2012-10-12

申请人： Bristol-Myers Squibb Company ,  Domantis Limited

发明人： Steven G. NADLER ,  James K. TAMURA ,  Laura PRICE ,  Robert P. REHFUSS ,  Suzanne J. SUCHARD ,  Anish SURI ,  James William BRYSON ,  Aaron YAMNIUK ,  Steven GRANT ,  Olga IGNATOVICH ,  Philip DREW

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K16/46

CPC分类号： C07K16/2878 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K16/283 ,  C07K16/2833 ,  C07K16/2875 ,  C07K16/2896 ,  C07K16/46 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

摘要： Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

公开(公告)号：US20200231676A1

公开(公告)日：2020-07-23

申请号：US16779059

申请日：2020-01-31

申请人： Bristol-Myers Squibb Company

发明人： Anish SURI ,  Steven G. NADLER ,  Christian P. LARSEN ,  Andrew Briane ADAMS

IPC分类号： C07K16/28 ,  A61K38/17 ,  A61K39/395 ,  C07K14/705

摘要： Methods of treating renal transplant rejection using anti-CD40L domain antibodies are provided. The anti-CD40L dAbs are less likely to cause platelet aggregation and thus cause thromboembolism. Appropriate anti-CD40L dAbs doses and administration regimens are also provided. Combination treatments for transplant rejection, particularly renal transplant rejection, using anti-CD40L dAbs, a CTLA4 mutant molecule (e.g., belatacept) and/or anti-CD28 optionally with conventional immunosuppressive renal transplant therapy are provided.

公开(公告)号：US20170051059A1

公开(公告)日：2017-02-23

申请号：US15122455

申请日：2015-03-19

申请人： Bristol-Myers Squibb Company

发明人： Anish SURI ,  Steven G. NADLER ,  Christian P. LARSEN ,  Andrew Briane ADAMS

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K38/17 ,  C07K14/705

CPC分类号： C07K16/2818 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/39541 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  C07K14/70521 ,  C07K14/70575 ,  C07K16/2875 ,  C07K2317/21 ,  C07K2317/40 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  A61K2300/00

摘要： Methods of treating renal transplant rejection using anti-CD40L domain antibodies are provided. The anti-CD40L dAbs are less likely to cause platelet aggregation and thus cause thromboembolism. Appropriate anti-CD40L dAbs doses and administration regimens are also provided. Combination treatments for transplant rejection, particularly renal transplant rejection, using anti-CD40L dAbs, a CTLA4 mutant molecule (e.g., belatacept) and/or anti-CD28 optionally with conventional immunosuppressive renal transplant therapy are provided.

摘要翻译： 提供了使用抗CD40L结构域抗体治疗肾移植排斥的方法。 抗CD40L dAb不太可能引起血小板聚集，从而引起血栓栓塞。 还提供了适当的抗CD40L dAb剂量和给药方案。 提供了使用抗CD40L dAb，CTLA4突变分子（例如belatacept）和/或任选用常规免疫抑制性肾移植治疗的抗CD28的移植排斥特别是肾移植排斥的组合治疗。